Abstract: A neural network system is proposed. The neural network can be trained by model-based reinforcement learning to select actions to be performed by an agent interacting with an environment, to perform a task in an attempt to achieve a specified result. The system may comprise at least one imagination core which receives a current observation characterizing a current state of the environment, and optionally historical observations, and which includes a model of the environment. The imagination core may be configured to output trajectory data in response to the current observation, and/or historical observations. The trajectory data comprising a sequence of future features of the environment imagined by the imagination core. The system may also include a rollout encoder to encode the features, and an output stage to receive data derived from the rollout embedding and to output action policy data for identifying an action based on the current observation.

Abstract: The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2? deoxyguanosine-5?-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein.

Abstract: Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.

Abstract: A neural network system is proposed to select actions to be performed by an agent interacting with an environment to perform a task in an attempt to achieve a specified result. The system may include a controller to receive state data and context data, and to output action data. The system may also include an imagination module to receive the state and action data, and to output consequent state data. The system may also include a manager to receive the state data and the context data, and to output route data which defines whether the system is to execute an action or to imagine. The system may also include a memory to store the context data.

Abstract: A neural network system is proposed. The neural network can be trained by model-based reinforcement learning to select actions to be performed by an agent interacting with an environment, to perform a task in an attempt to achieve a specified result. The system may comprise at least one imagination core which receives a current observation characterizing a current state of the environment, and optionally historical observations, and which includes a model of the environment. The imagination core may be configured to output trajectory data in response to the current observation, and/or historical observations. The trajectory data comprising a sequence of future features of the environment imagined by the imagination core. The system may also include a rollout encoder to encode the features, and an output stage to receive data derived from the rollout embedding and to output action policy data for identifying an action based on the current observation.

Abstract: A neural network system is proposed to select actions to be performed by an agent interacting with an environment to perform a task in an attempt to achieve a specified result. The system may include a controller to receive state data and context data, and to output action data. The system may also include an imagination module to receive the state and action data, and to output consequent state data. The system may also include a manager to receive the state data and the context data, and to output route data which defines whether the system is to execute an action or to imagine. The system may also include a memory to store the context data.

Abstract: A neural network system is proposed. The neural network can be trained by model-based reinforcement learning to select actions to be performed by an agent interacting with an environment, to perform a task in an attempt to achieve a specified result. The system may comprise at least one imagination core which receives a current observation characterizing a current state of the environment, and optionally historical observations, and which includes a model of the environment. The imagination core may be configured to output trajectory data in response to the current observation, and/or historical observations. The trajectory data comprising a sequence of future features of the environment imagined by the imagination core. The system may also include a rollout encoder to encode the features, and an output stage to receive data derived from the rollout embedding and to output action policy data for identifying an action based on the current observation.

Abstract: A neural network system is proposed. The neural network can be trained by model-based reinforcement learning to select actions to be performed by an agent interacting with an environment, to perform a task in an attempt to achieve a specified result. The system may comprise at least one imagination core which receives a current observation characterizing a current state of the environment, and optionally historical observations, and which includes a model of the environment. The imagination core may be configured to output trajectory data in response to the current observation, and/or historical observations. The trajectory data comprising a sequence of future features of the environment imagined by the imagination core. The system may also include a rollout encoder to encode the features, and an output stage to receive data derived from the rollout embedding and to output action policy data for identifying an action based on the current observation.

Abstract: A neural network system is proposed to select actions to be performed by an agent interacting with an environment to perform a task in an attempt to achieve a specified result. The system may include a controller to receive state data and context data, and to output action data. The system may also include an imagination module to receive the state and action data, and to output consequent state data. The system may also include a manager to receive the state data and the context data, and to output route data which defines whether the system is to execute an action or to imagine. The system may also include a memory to store the context data.

Abstract: Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.

Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19 , are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.

Abstract: An all-wheel drive vehicle driveline that includes a housing assembly with a housing structure and a cover. In one form, components of the driveline can be assembled to the housing structure and cover in such a way that an intermediate shaft, which is assembled to the cover, and an input shaft, which can be rotatably mounted to the housing structure, can be slidably engaged to one another. In another form, the cover defines a reservoir that is configured to feed fluid to a pump that is mounted to the cover.

Abstract: The present invention provides polypeptide domains of C. difficile toxin B (B1, B2, B3, B4) and complexes between the polypeptides and antibodies that bind specifically for the polypeptide. Methods of using the polypeptides to generate antibodies are also provided.

Abstract: An all-wheel drive vehicle driveline that includes a housing assembly with a housing structure and a cover. In one form, components of the driveline can be assembled to the housing structure and cover in such a way that an intermediate shaft, which is assembled to the cover, and an input shaft, which can be rotatably mounted to the housing structure, can be slidably engaged to one another. In another form, the cover defines a reservoir that is configured to feed fluid to a pump that is mounted to the cover.

Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.

Abstract: A method in a warehouse management system for providing instructions to a user, comprising: receiving a table in a database of the warehouse management system, the table defining the instructions, one or more of the columns of the table containing data and image references pertaining to respective warehouse storage items associated with the instructions; adding an expression column to the table, the expression column for defining a combination of the data and image references pertaining to the respective warehouse storage items in accordance with the instructions; adding markup language code to the expression column for customizing a graphical presentation of the combination; generating the graphical presentation of the combination from the markup language code; and, displaying the graphical presentation on a display screen of the warehouse management system, thereby providing the instructions to the user in a graphical format.

Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Abstract: This application covers a novel PEGylated interferon and a novel crystalline form of interferon which are useful, inter alia, for detailed structural analysis of interferon as well as treatment and prevention of viral infections and hyperproliferative diseases such as leukemia.

Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Abstract: The present invention provides, inter alia, crystals of the MEK1 polypeptide which are particularly useful for structure based drug design as well as methods of use thereof.